Despite the challenges inherent in biosimilars, they have a fairly high probability of success, said Edric Engert, managing director of Abraxeolus Consulting, in a presentation at the 14th Biosimilars Summit, held January 22-23, 2019, in Alexandria, Virginia.
Despite the challenges inherent in biosimilars, they have a fairly high probability of success, said Edric Engert, managing director of Abraxeolus Consulting, in a presentation at the 14th Biosimilars Summit, held January 22-23, 2019, in Alexandria, Virginia.
According to Engert, people continue to see biosimilars as a particularly risky endeavor largely because of the difficulty of developing these products, challenges related to pricing and uptake, the number of potential competitors, and innovator defenses, among other factors.
Despite challenges, said Engert, it is possible to manage risks in order to capture rewards. He provided a hypothetical example of a biosimilar developer that was able to develop a product (for which the reference product has $4 billion in sales) in 7 years and launch it in 10 years.
Assuming 4 biosimilar competitors, and 80% eventual biosimilar penetration, a developer could start with a 35% discount to the reference product and continue to drop that price by 8% each year while also investing $13 million in marketing and hiring a sales force of representatives, and they company will have a net present value of $480 million for the product. Even assuming the hypothetical product’s launch was delayed by as much as 4 years, he said, the net present value would still be $265 million.
Some basic steps can bring discipline to risk identification to reap those rewards, said Engert. First, developers should pick their highest priorities to focus on first: “You can’t do everything at once.” Once the key issues have been identified, “it’s all about identifying the downstream implications.”
For challenges like intellectual property issues, for example, a developer might need to forge an internal legal team, join a trade association, or engage in contingency planning. If commercialization issues are the concern, the company might choose to engage with HHS, deepen its policy and government affairs understanding, and seek to truly understand the complexity of its portfolio choices.
Next, it’s important for developers to understand how operations will be affected, then enter into detailed planning and refine those plans through honestly assessing internal challenges. “We’re so focused on the risks that we’re facing as an industry…it’s very easy sometimes to neglect the things we’re facing within ourselves.”
For example, in assessing a portfolio, it’s useful to remember that, currently, oncology is number 1 in terms of the number of projects in the innovator pipeline; thus, oncology is also where future losses of patent exclusivity will occur. Developers need to make a strategic decision on how big a role oncology will play in their portfolios, and that involves understanding the buy-and-bill landscape for oncology centers and investigating all available settings for oncology products.
In considering marketing their drugs, biosimilar developers will have to plan to engage in activities that resemble a branded launch. They will need to consider their core message development, engage healthcare provider advisory boards, and engage in public relations, among other activities. Market access undertakings will involve assessing CMS reimbursement, creating a net pricing model, and contracting with group purchasing organizations. Distribution will require early planning and refinement of approach.
Through early planning in these areas, concluded Engert, developers can achieve substantial rewards from biosimilars. “Yes there are lots of risks. And we should be talking about the risks,” he said. “But don’t lose sight of the ball here. There is a significant return.”
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.